Senior Vice President, Human Resources andCorporate Affairs
SAN RAFAEL, Calif.—Sept. 4 saw the official entryof Richard Ranieri as senior vice president of human resources and corporate affairsat BioMarin, bringing "a wealth of human resources experience to the company aswe continue our rapid growth," according to CEO Jean-Jacques Bienaime. "He hasthe depth and breadth of global experience that BioMarin needs as it scales itsoperations to meet its expanding business. As an experienced senior level humanresources executive in the biopharma industry, Rich is extremely well-qualifiedto fill this leadership role and will be an instrumental member of theorganization."
Ranieri most recently served as executive vicepresident of human resources at Dendreon Corp. from 2010 to 2013 where he was responsiblefor all aspects of human resources and oversaw the expansion of the workforcefrom 150 to 2,000 employees. Prior to Dendreon, he was the executive vicepresident of human resources and administration at Sepracor Inc.
Jeryl L. Hilleman
Chief Financial Officer
SAN DIEGO—Ocera Therapeutics, a clinical-stagebiopharmaceutical company focused on acute and chronic orphan liver diseases, onSept. 3 brought in Jeryl L. Hilleman as its newest chief financial officer. Shereplaces Dana McGowan, who will continue with the company during a transitionperiod in which the company plans to move its headquarters to NorthernCalifornia.
"I am very pleased that an executive withJeri's skills, global experience and proven expertise is joining our seniormanagement team," said Dr. Linda Grais, president and CEO of Ocera. "Herextensive public company experience, both in and outside of the biotechindustry, combined with her operational leadership, will be invaluable as weexecute on our immediate business priority to initiate a Phase IIb clinicaltrial of OCR-002 for the treatment of acute hepatic encephalopathy."
Hilleman has more than two decades experience asCFO of both private and public companies, including taking four companiespublic. Most recently, she has provided independent financial and strategic consultingfor biotech and cleantech companies. From 2008 to 2012, Hilleman served as CFOof Amyris Inc., a multi-national, renewable products company based inCalifornia and Brazil.
AMAG Pharmaceuticals Inc.
LEXINGTON, Mass.—AMAG Pharmaceuticals recentlyannounced that Barbara Deptula, former executive vice president and chiefcorporate development officer of Shire PLC, has been elected to AMAG's board ofdirectors, effective Sept. 6. Deptula brings to the AMAG board broad-basedcorporate development expertise obtained through her 30-year career in a varietyof biotechnology and multinational pharmaceutical organizations. During hertenure at Shire, the company deployed nearly $5 billion dollars acquiring arange of companies and products, and established an independent venture capitalarm.
"Barbara has had a successful career as asenior executive in business development and corporate strategy, and she bringsto our board a skill set that complements our current board and AMAG'sstrategic focus," said Michael Narachi, chairman of the board of AMAG."We are pleased to have Barbara join us as we continue to grow our currentproducts and seek additional products to add to our portfolio."
Cold Spring Harbor Laboratory
Teri F. Willey
Vice President of Business Development andTechnology Transfer
COLD SPRING HARBOR, N.Y.—Cold Spring HarborLaboratory recently brought on Teri F. Willey for the newly created position ofvice president of business development and technology transfer. In this role,she will direct CSHL's commercialization and technology transfer activities,including patenting, licensing, company start-ups and corporate partnershipsand collaborations.
Willey joins CSHL from Mount Sinai Medical Center,where she successfully led the center's technology transfer and businessdevelopment efforts. John Maroney, who previously had responsibility fortechnology transfer activities, will continue in his role at CSHL as generalcounsel.
"CSHL's transformative discoveries over many yearsin such areas as cancer, autism and other neuropsychiatric disorders, genomeanalysis, plant biology and biofuels have significant commercial applicationsthat will improve diagnostic and therapeutic approaches in the clinic as wellas in agriculture and energy production," said CSHL President Bruce Stillman. "Theappointment of Teri Willey to this new position will ensure that our researchadvances are applied to society's biggest challenges in healthcare, theenvironment and world hunger and will enable us to maximize the economicpotential of the biomedical research cluster on Long Island."
Richard T. Kenney, M.D.
Chief Medical Officer
SEATTLE—Dr. Richard T. Kenney recently joined onto Immune Design, a biotech company focused on the development of novelimmune-based therapies for cancer and other human diseases, as its chiefmedical officer. He brings extensive experience in the research, clinical andregulatory fields from the biopharmaceutical industry, public health andgovernmental environments—including having previously overseen the design,conduct and advancement of multiple clinical programs at Crucell, Vical, andGSK Biologicals. In this new position, Kenney will lead the clinical developmentteam at Immune Design to advance the company's novel immunotherapy product candidates.
"Rick is an experienced, respected researcherin drug development with a successful career in advancing novelimmunotherapies," said Dr. Carlos Paya, president and CEO of Immune Design."We are very pleased to have him join Immune Design's executive managementteam and know that his demonstrated skills and deep experience in the fields ofcancer, vaccines, and adjuvants will be an asset as we advance ourfirst-in-class cancer immunotherapy programs, including G305 and LV305, intothe clinic."
George Lundberg, M.D.
Chief Medical Officer
SAN FRANCISCO—CollabRx has announced theappointment of Dr. George Lundberg, as its chief medical officer, though hewill also continue in his position as editor-in-chief and chair of the EditorialAdvisory Board of CollabRx.
Lundberg has more than 30 years combinedexperience as editor-in-chief of TheJournal of the American Medical Association), the 10 American MedicalAssociation specialty journals, AmericanMedical News, Medscape, The Medscape Journal, e-Medicine from Web MD, andMedPage Today from Everyday Health. A frequent lecturer, radio and televisionguest, and a member of the Institute of Medicine of the National Academy ofSciences, the Industry Standard dubbed Lundberg "Online Healthcare'sMedicine Man" in 2000. Prior to joining CollabRx in 2010, Dr. Lundbergserved as the president of the American Society for Clinical Pathology, professor of pathology and associate director of laboratories at the LosAngeles County/USC Medical Center for 10 years, and for five years was the professor and chair of pathology at the University of California, Davis.
Harvard Bioscience Inc.
Jeffrey A. Duchemin
Chief Executive Officer
HOLLISTON, Mass.—Harvard Bioscience recentlyannounced the hiring of Jeffrey A. Duchemin as Harvard Bioscience's new CEO.David Green, who has served as Harvard Bioscience's interim CEP since May 15,has resigned from that interim position and will continue in his capacity asthe president of Harvard Bioscience until the completion of the company'sspin-off of its regenerative medicine subsidiary. Prior to joining HarvardBioscience, Duchemin spent 16 years with Becton Dickinson in progressive sales,marketing and executive leadership positions across BD's three businesssegments; BD Medical Systems, BD Diagnostic Systems, and BD Biosciences.
Earl Lewis, Chairman of Harvard Bioscience's boardof directors, said: "Mr. Duchemin is a proven global executive withextensive experience in the fields of life science research, diagnostic and medicaldevices. The board of directors is excited to have Jeff join Harvard Bioscienceand is looking forward to working with him to bring further success to the company."